Synthetic Immuno-Oncology: Multi-Modal, Self-Limiting Solid Tumor Therapies - MMSLSTT

This white paper delivers a comprehensive, industry‑grade blueprint for a self‑limiting, multi‑modal synthetic immuno‑oncology platform targeting solid tumors. It integrates four core modalities—logic‑gated T cells, oncolytic virotherapy, AI‑designed genetic circuits, and Evo2 mutation‑effect prediction—into a coordinated “hunter” therapy capable of discriminating malignant from healthy tissue, penetrating stromal barriers, resisting immunosuppression, and enforcing robust safety controls. The technology landscape section details advanced CAR‑T logic gates, contextual microenvironmental sensors, chemokine homing modules, and tumor‑restricted oncolytic virus payloads. AI‑driven promoter/enhancer design and in silico variant screening optimize potency, specificity, and manufacturability. The integration strategy outlines synchronized CAR‑T/OV co‑therapy, modular circuit assembly, and real‑time PET/MRI monitoring. Safety and regulatory frameworks incorporate dual orthogonal kill‑switches, miRNA gating, GMP‑friendly editing, and ethical oversight. A staged preclinical‑to‑clinical development plan, supported by comparative model analyses, survival data, and a Gantt‑mapped timeline, targets clinical proof‑of‑concept within eight years and broad efficacy by year ten. Appendices provide SOP templates, risk registers, regulatory checklists, and vector/circuit specifications to enable immediate program initiation. This work is intended for translational researchers, biotech program leads, CMC/regulatory teams, and strategic investors seeking a fully actionable, peer‑aligned roadmap for next‑generation solid tumor immunotherapy.